Early in 1997, Genzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex's first product, RenaGel. Geltex was a young biotech research company with only two products in its pipeline, and they didn't have the resources necessary to launch RenaGel on their own. Genzyme, on the other hand, was a quickly growing company that experienced revenues of $518 million in 1996. They were attracted to the joint venture with Geltex …showed first 75 words of 2191 total…

…showed last 75 words of 2191 total…summarize: *<Tab/>What is the likely enterprise value of the joint venture?<Tab/>($29,513,370) *<Tab/>How much of the venture should Genzyme acquire?<Tab/>0% *<Tab/>How much should Genzyme pay for its interest?<Tab/><Tab/>$0 Calculations for these numbers can be found in Appendix C, Exhibits 1 & 2